



DIL Complex, Ghodbunder Road, Thane(W)- 400 610, INDIA.

Tel. : +91-22-6798 0888  
 : +91-22-6798 0800  
 Fax : +91-22-6798 0999  
 Email : contact@dil.net  
 www.dil.net

**DIL Limited**

Unaudited financial results for the period ended September 30, 2009.

(Rupees in Lakhs)

Sr.No.	Particulars	Standalone					Consolidated				
		Quarter ended		Half year ended		Audited Year Ended March 31,	Quarter ended		Half year ended		Audited Year Ended March 31,
		September 30,		September 30,			September 30,		September 30,		
		2009 (Note 1)	2008 (Note 1)	2009 (Note 1)	2008 (Note 1)	2009 (Note 1)	2009 (Note 1)	2008 (Note 1)	2009 (Note 1)	2008 (Note 1)	2009 (Note 1)
1	a) Net Sales/ Income from Operations	323.93	301.91	680.20	599.70	1,205.58	1,585.77	1,834.00	3,705.55	3,074.64	6,594.81
	b) Other Operating Income	19.85	4.61	24.13	9.26	18.08	59.41	25.13	62.23	62.91	61.19
	Net sales & other operating income	343.78	306.52	704.33	608.96	1,223.66	1,645.18	1,859.13	3,767.78	3,137.55	6,656.00
2	Expenditure										
	a) (Increase)/decrease in stock-in-trade and work in process	-	-	-	-	-	(144.99)	67.40	(157.02)	(24.50)	182.51
	b) Consumption of raw-materials	-	-	-	-	-	378.25	397.48	843.98	685.89	1,327.30
	c) Purchase of finished goods	-	-	-	-	-	59.62	-	59.62	-	-
	d) Employees cost	54.52	53.61	107.99	120.78	222.39	409.88	436.33	864.60	856.66	1,754.38
	e) Depreciation	28.44	24.56	55.38	48.54	109.18	124.71	110.46	256.88	210.81	475.29
	f) Processing charges	-	-	-	-	-	48.94	86.04	142.26	116.55	257.20
	g) Exchange loss (net)	-	1.19	-	1.19	2.32	-	-	-	-	-
	h) Legal & professional expenses	97.79	26.78	111.75	38.01	166.87	157.03	60.80	226.70	120.78	412.41
	i) Repairs & maintenance	67.24	64.44	83.07	87.58	151.48	95.58	88.42	135.79	124.00	240.34
	j) Provision for impairment in the value of goodwill	-	-	-	-	-	-	-	-	-	121.00
	j) Other expenditure	45.45	43.32	94.95	90.98	240.53	341.08	365.87	684.47	692.69	1,419.83
	k) Total expenditure (a to k)	293.44	213.90	453.14	387.08	892.77	1,470.10	1,612.80	3,057.28	2,782.88	6,190.26
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	50.34	92.62	251.19	221.88	330.89	175.08	246.33	710.50	354.67	465.74
4	Other income	7.30	-	7.30	5.00	17.21	8.42	6.17	10.19	28.38	104.57
5	Profit before Interest & Exceptional Items (3+4)	57.64	92.62	258.49	226.88	348.10	183.50	252.50	720.69	383.05	570.31
6	Interest	0.88	0.93	1.89	1.40	115.05	41.22	39.66	90.11	71.43	302.17
7	Profit after interest but before Exceptional Items (5-6)	56.76	91.69	256.60	225.48	233.05	142.28	212.84	630.58	311.62	268.14
8	Exceptional items										
	a) Depreciation written back	-	29.82	-	187.94	179.72	-	23.90	-	361.00	364.83
	b) Profit on Sale of Investment in Subsidiary	607.83	-	607.83	-	-	495.79	-	495.79	-	-
9	Profit/(Loss) from ordinary Activities before tax (7+8)	664.59	121.51	864.43	413.42	412.77	638.07	236.74	1,126.37	672.62	632.97
10	Tax expense	103.44	22.19	153.24	96.13	70.78	114.10	50.83	230.88	157.22	179.67
11	Net profit/(loss) from Ordinary Activities after tax (9-10)	561.15	99.32	711.19	317.29	341.99	523.97	185.91	895.49	515.40	453.30
12	Provision for tax in respect of earlier years written back	0.09	-	0.09	-	(0.65)	(2.81)	-	(2.81)	(0.12)	(0.77)
13	Net Profit/(Loss) for the period (11+12)	561.24	99.32	711.28	317.29	341.34	521.16	185.91	892.68	515.28	452.53
14	Share of minority interest	-	-	-	-	-	(8.43)	37.87	(2.27)	95.48	131.65
15	Share of profit / (loss) in associate Companies	-	-	-	-	-	(15.49)	-	(15.49)	-	-
16	Net profit/(loss) after minority interest and share in Associates	561.24	99.32	711.28	317.29	341.34	497.24	223.78	874.92	610.76	584.18
17	Paid-up equity share capital (Face value Rs 10/- per share)	229.32	229.32	229.32	229.32	229.32	229.32	229.32	229.32	229.32	229.32
18	Reserves excluding revaluation reserves	-	-	-	-	6,735.36	-	-	-	-	7,708.99
19	a) Basic and diluted EPS (Rs./Share) before extraordinary items	24.47	4.33	31.02	13.84	14.88	21.68	9.76	38.15	26.63	25.47
	b) Basic and diluted EPS (Rs./Share) after extraordinary items	24.47	4.33	31.02	13.84	14.88	21.68	9.76	38.15	26.63	25.47
20	Public shareholding										
	- Number of shares	926,905	926,905	926,905	926,905	926,905	926,905	926,905	926,905	926,905	926,905
	- Percentage to shareholding	40.42%	40.42%	40.42%	40.42%	40.42%	40.42%	40.42%	40.42%	40.42%	40.42%
21	Promoters and promoter group shareholding										
	a) Pledged/ Encumbered										
	- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage to shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage to shares (as a % of the total share capital of the Company)	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered										
	- Number of shares	1,366,293	1,366,293	1,366,293	1,366,293	1,366,293	1,366,293	1,366,293	1,366,293	1,366,293	1,366,293
	- Percentage to shareholding (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage to shares (as a % of the total share capital of the Company)	59.58%	59.58%	59.58%	59.58%	59.58%	59.58%	59.58%	59.58%	59.58%	59.58%

Refer note No. 2

Refer note No. 6

Refer note No. 3

Refer note No. 4

For quarter only and not annualised except for year end results

SIGNED FOR IDENTIFICATION  
 BY  
  
 S. R. BATLIBOI & ASSOCIATES  
 MUMBAI

Segment-wise Revenue, Results and Capital employed under Clause 41 of the Listing agreement

Particulars	Standalone					Consolidated				
	Quarter ended		Half year ended		Audited Year Ended March 31,	Quarter ended		Half year ended		Audited Year Ended March 31,
	September 30,		September 30,			September 30,		September 30,		
	2009	2008	2009	2008	2009	2008	2009	2008	2009	
(Note 1)	(Note 1)	(Note 1)	(Note 1)	(Note 1)	(Note 1)	(Note 1)	(Note 1)	(Note 1)		
Segment revenue										
- Bulk drugs/chemicals	-	-	-	-	-	1,014.41	1,105.65	2,445.41	1,686.76	3,624.48
- Research & development	****	-	-	-	-	408.56	541.09	854.09	997.80	2,151.47
- Treasury & others	343.78	306.52	704.33	608.96	1,222.42	347.00	308.26	715.34	617.01	1,235.23
- Entertainment	-	-	-	-	1.24	-	-	-	-	1.24
Total	343.78	306.52	704.33	608.96	1,223.66	1,769.97	1,955.00	4,014.84	3,301.57	7,012.42
Less : Inter-segment revenue	-	-	-	-	-	124.79	95.87	247.06	164.02	356.42
Net sales/income from operation	343.78	306.52	704.33	608.96	1,223.66	1,645.18	1,859.13	3,767.78	3,137.55	6,656.00
Segment results {profit/(loss) before interest and tax}										
- Bulk drugs/chemicals	-	-	-	-	-	70.85	136.65	496.20	165.18	244.52
- Research & development	****	-	-	-	-	59.16	16.77	(26.77)	(29.08)	4.31
- Treasury & others	65.47	108.13	281.79	248.64	391.12	64.79	109.79	278.14	247.08	258.81
- Entertainment	(15.13)	(15.51)	(30.60)	(26.76)	(60.23)	(15.13)	(15.51)	(30.60)	(26.76)	(60.23)
Total	50.34	92.62	251.19	221.88	330.89	179.67	247.70	716.97	356.42	447.41
Less: Inter-segment results	-	-	-	-	-	4.59	1.37	6.47	1.75	(18.33)
Total	50.34	92.62	251.19	221.88	330.89	175.08	246.33	710.50	354.67	465.74
Less : Interest expense	***	0.88	0.93	1.89	1.40	115.05	39.66	90.11	71.43	302.17
Add: unallocable income	7.30	-	7.30	5.00	17.21	8.42	6.17	10.19	28.38	104.57
Add: Exceptional items	-	-	-	-	-	-	-	-	-	-
a) Depreciation written back	*	-	29.82	-	187.94	-	23.90	-	361.00	364.83
b) Profit on Sale of Investment in Subsidiary	****	607.83	-	607.83	-	495.79	-	495.79	-	-
Profit before tax	664.59	121.51	864.43	413.42	412.77	638.07	236.74	1,126.37	672.62	632.97
Capital employed (Segment assets)										
Less Segment liabilities)										
- Bulk Drugs/chemicals								3,149.05	2,917.62	2,429.69
- Research & development	****							-	1,794.14	1,673.06
- Treasury & others			7,396.09	7,144.68	6,922.98			5,101.61	3,779.42	3,676.34
- Entertainment			16.65	12.31	10.00			16.65	12.31	10.00
Unallocated			263.23	186.07	31.70			639.78	225.25	456.75
Total Capital employed			7,675.97	7,343.06	6,964.68			8,907.09	8,728.74	8,243.84

\* Refer note No. 2  
\*\* Refer note No. 6  
\*\*\* Refer note No. 3  
\*\*\*\* Refer note No. 4


NOTES:

- DIL Limited (the Company) is in the business of renting properties, motion film production and distribution and in treasury operations. The Company also has strategic investments in subsidiaries, associates and joint venture which are engaged in Drug discovery and development services, manufacturing of bulk drugs and development of discoidal electrical motor technology. The above unaudited financial results are presented on a stand alone basis as well as on a consolidated basis so as to include the operations of the Company's subsidiaries, associates and joint venture (Group).
- In the previous year ended March 31, 2009, the Company and its subsidiaries changed its method of providing depreciation on fixed assets from Written Down Value Method to Straight Line Method. As a result of the change, the Company wrote back depreciation of Rs. 179.72 Lakhs and Rs 364.83 Lakhs in the standalone and consolidated financial results for that year respectively.
- Interest of the year ended March 31, 2009 includes interest on income tax amounting to Rs. 111.44 Lakhs, received in earlier years refunded back to Income Tax Department by the Company.
- During the current quarter, the Company has executed a Share Purchase and a Shareholder' Agreement (Agreements) on August 31, 2009 with Evotec AG and transferred 2,54,94,000 equity shares of Rs. 2/- each. i.e. 70% of the paid up equity share capital of Research Support International Private Limited (RSIPL) for a consideration of Rs. 1117 lakhs, as a result of which w.e.f. September 1, 2009 RSIPL is no longer a subsidiary of the Company. Accordingly the Company's interest in RSIPL has been accounted as "Interest in Associate Company" in the consolidated financial statements. The unaudited consolidated quarterly financial results includes the results of the Associate & its Subsidiaries viz. Evotec India Private Limited (formerly known as Research Support International Private Limited) and its 51% subsidiary viz Evotec - RSIL Limited on basis of unreviewed financial statements prepared by the management.
- During the year ended March 31, 2009 the Company's subsidiary has entered into an agreement for transfer of the throat lozenge business along with the trademark "Astrasept" and the related moveable assets for a consideration of Rs. 8 Lakhs, to its wholly owned subsidiary G.I. Biotech Private Limited (G.I.). Simultaneously company has also entered into a share transfer agreement with Ronator Investments Limited (RI) a company incorporated under the legal provisions of Cyprus, to transfer its entire shareholding in G.I in four instalments to be completed by 10th February 2009 for a total consideration of USD 400,000. In accordance with the share transfer agreement during the previous year the Company sold 3750 shares for consideration of USD 150,000 and recorded a profit of Rs 70.64 Lakhs. The time limit stipulated for completion of the share transfer agreement and completion of transaction has been extended further to 31st March 2010.
- The Company has invested an aggregate of Rs. 188.51 Lakhs in VasKo Glider s.r.o. Czechoslovakia, a joint venture in the form of basic capital of Rs. 1.96 Lakhs and voluntary capital of Rs. 186.55 Lakhs. The joint venture is involved in development and manufacture of wheel chair based on discoidal electrical motor, the patent for which has recently been registered by U.S./ Indian / Australian patent authorities. The Company believes that the said investment has long term potential on commercialisation. Hence, no provision for diminution in value of investment has been considered in the standalone financial statements. The Statutory Auditors of the Company are unable to express their opinion on the carrying value of this investment. However during the year ended March 31, 2009, the Company has recognised an impairment loss in the value of goodwill arising out of the said investment in the consolidated financial statements.
- The expenses of the Company in stand alone results are stated net of recovery from subsidiaries.
- Previous year's / period's figures have been regrouped wherever necessary and are not comparable in view of explanation given in Note no. 4 above.
- There were no investor complaints pending at the beginning and at the end of the quarter ended September 30, 2009. 15 (fifteen) complaints were received and resolved during the quarter ended September 30, 2009.
- The above unaudited quarterly results have been taken on record by the Audit Committee and thereafter by the Board of Directors in its meeting held on October 29, 2009.

THANE  
October 29, 2009

For DIL Limited

  
Krishna Datta  
Managing Director

SIGNED FOR IDENTIFICATION  
BY  
  
S. R. BATLIBOI & ASSOCIATES  
MUMBAI

dil ltd.